levofloxacin inhaled
Selected indexed studies
- Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. (Future Microbiol, 2021) [PMID:34384254]
- Levofloxacin. (, 2026) [PMID:31424764]
- Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging. (Pharmaceutics, 2021) [PMID:34959333]
_Worker-drafted node — pending editorial review._
Connections
levofloxacin inhaled is a side effect of
Sources
- Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review. (2015) pubmed
- Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. (2022) pubmed
- Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. (2021) pubmed
- Levofloxacin. (2026) pubmed
- Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging. (2021) pubmed
- [Legionnaires disease]. (2007) pubmed
- New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population. (2016) pubmed
- Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. (2015) pubmed
- Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. (2021) pubmed
- Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis. (2023) pubmed